The effects of sonidegib, when given in combination with rimfampicin and ketoconazole, on CYP3A4 biomarker levels in healthy volunteers.

Trial Profile

The effects of sonidegib, when given in combination with rimfampicin and ketoconazole, on CYP3A4 biomarker levels in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs Sonidegib (Primary) ; Ketoconazole; Rifampicin
  • Indications Basal cell cancer; Chronic myeloid leukaemia; Haematological malignancies; Medulloblastoma; Multiple myeloma; Myelofibrosis; Pancreatic cancer; Solid tumours
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 25 Jan 2017 Results (n=45) published in the Drug Metabolism and Disposition.
    • 18 Apr 2014 Results published in the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 18 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top